Q4 2025 · 13F-HR
Catalio Capital Management, LPholdings as filed
Filed 2026-02-17 · accession 0001958125-26-000002
$565.8M
Reported value
45
Positions
2025-12-31
Period end
The Brief · Catalio Capital Management, LP · Q4 2025
AI · grounded in 13F
Catalio Capital Management, LP exited its position in ABBV for a reduction of $35.85M. The fund also closed its position in BBIO for $32.34M and trimmed its holdings in ISRG by 61.86%. To offset these exits, the fund established new positions in GILD for $35.51M and BMY for $34.95M.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 375558103 | GILD | GILEAD SCIENCES INC | $35.5M | 6.28% | 289,312 | Common | SOLE |
| 110122108 | BMY | BRISTOL-MYERS SQUIBB CO | $34.9M | 6.18% | 647,899 | Common | SOLE |
| 101137107 | BSX | BOSTON SCIENTIFIC CORP | $34.4M | 6.07% | 360,428 | Common | SOLE |
| 107924102 | BBOT | BRIDGEBIO ONCOLOGY THERAPEUT | $31.4M | 5.55% | 410,700 | Common | SOLE |
| 532457108 | LLY | ELI LILLY & CO | $27.9M | 4.92% | 25,923 | Common | SOLE |
| 252828108 | DNTH | DIANTHUS THERAPEUTICS INC | $26.9M | 4.76% | 653,572 | Common | SOLE |
| 04351P101 | ASNDUSD | ASCENDIS PHARMA A/S | $25.4M | 4.49% | 119,265 | Common | SOLE |
| 87164F105 | SNDX | SYNDAX PHARMACEUTICALS INC | $25.1M | 4.44% | 1,196,807 | Common | SOLE |
| 478160104 | JNJ | JOHNSON & JOHNSON | $25.0M | 4.42% | 120,840 | Common | SOLE |
| 75886F107 | REGN | REGENERON PHARMACEUTICALS | $23.0M | 4.07% | 29,797 | Common | SOLE |
| 86366E106 | GPCR | STRUCTURE THERAPEUTICS INC | $17.6M | 3.11% | 252,901 | Common | SOLE |
| 834203309 | SLNO | SOLENO THERAPEUTICS INC | $16.7M | 2.95% | 360,340 | Common | SOLE |
| 23282W605 | CYTK | CYTOKINETICS INC | $16.4M | 2.90% | 258,381 | Common | SOLE |
| 28176E108 | EW | EDWARDS LIFESCIENCES CORP | $15.9M | 2.82% | 187,048 | Common | SOLE |
| 46120E602 | ISRG | INTUITIVE SURGICAL INC | $15.4M | 2.72% | 27,209 | Common | SOLE |
| 632307104 | NTRA | NATERA INC | $14.3M | 2.52% | 62,273 | Common | SOLE |
| 00650F109 | ADPT | ADAPTIVE BIOTECHNOLOGIES COR | $13.3M | 2.36% | 821,195 | Common | SOLE |
| 00370M103 | ABVX | ABIVAX SA | $13.3M | 2.35% | 98,514 | Common | SOLE |
| 868459108 | SUPN | SUPERNUS PHARMACEUTICALS INC | $12.8M | 2.26% | 257,465 | Common | SOLE |
| 35168W103 | GUTS | FRACTYL HEALTH INC | $12.1M | 2.14% | 5,491,866 | Common | SOLE |
| 603170101 | MLYS | MINERALYS THERAPEUTICS INC | $12.0M | 2.13% | 331,849 | Common | SOLE |
| 71722W107 | PHAT | PHATHOM PHARMACEUTICALS INC | $11.6M | 2.05% | 698,996 | Common | SOLE |
| 000899104 | ADMA | ADMA BIOLOGICS INC | $10.3M | 1.82% | 564,461 | Common | SOLE |
| 03940C100 | ACLXGBX | ARCELLX INC | $10.2M | 1.80% | 156,109 | Common | SOLE |
| 26818M108 | DYN | DYNE THERAPEUTICS INC | $10.2M | 1.80% | 519,715 | Common | SOLE |
| 254604101 | IRON | DISC MEDICINE INC | $8.8M | 1.55% | 110,427 | Common | SOLE |
| 67576A100 | OCUL | OCULAR THERAPEUTIX INC | $8.7M | 1.53% | 714,501 | Common | SOLE |
| 81734D104 | SEPN | SEPTERNA INC | $8.2M | 1.45% | 294,360 | Common | SOLE |
| 74365U107 | TARA | PROTARA THERAPEUTICS INC | $7.7M | 1.36% | 1,446,254 | Common | SOLE |
| N90064101 | QURE | UNIQURE NV | $6.9M | 1.22% | 288,345 | Common | SOLE |
| 68062P106 | OLMA | OLEMA PHARMACEUTICALS INC | $6.7M | 1.18% | 267,058 | Common | SOLE |
| 880881107 | 430 | TERNS PHARMACEUTICALS INC | $5.5M | 0.98% | 136,958 | Common | SOLE |
| 90400D108 | RARE | ULTRAGENYX PHARMACEUTICAL IN | $3.7M | 0.66% | 162,550 | Common | SOLE |
| 42238D107 | HTFL | HEARTFLOW INC | $3.3M | 0.59% | 113,857 | Common | SOLE |
| 384747101 | GRAL | GRAIL INC | $2.6M | 0.46% | 30,313 | Common | SOLE |
| 359616109 | FULC | FULCRUM THERAPEUTICS INC | $2.3M | 0.40% | 201,301 | Common | SOLE |
| 090168105 | BLLN | BILLIONTOONE INC | $2.1M | 0.37% | 25,505 | Common | SOLE |
| 28617K101 | ELDN | ELEDON PHARMACEUTICALS INC | $1.9M | 0.34% | 1,259,820 | Common | SOLE |
| 44916K106 | HYPR | HYPERFINE INC | $1.3M | 0.23% | 1,320,041 | Common | SOLE |
| 697947109 | PVLA | PALVELLA THERAPEUTICS INC NE | $1.1M | 0.19% | 10,452 | Common | SOLE |
| 48576U205 | KPTI | KARYOPHARM THERAPEUTICS INC | $1.1M | 0.19% | 142,984 | Common | SOLE |
| 59102M104 | MGX | METAGENOMI INC | $856,969 | 0.15% | 528,993 | Common | SOLE |
| N0731H103 | ATAI | ATAI BECKLEY NV | $805,149 | 0.14% | 196,858 | Common | SOLE |
| 690145206 | OM | OUTSET MED INC | $438,815 | 0.08% | 118,279 | Common | SOLE |
| 81728A207 | SNSE | SENSEI BIOTHERAPEUTICS INC | $157,041 | 0.03% | 14,718 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.